314 related articles for article (PubMed ID: 25883030)
21. New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?
Feng SS
Nanomedicine (Lond); 2006 Oct; 1(3):297-309. PubMed ID: 17716160
[TBL] [Abstract][Full Text] [Related]
22. Polymeric vesicles: from drug carriers to nanoreactors and artificial organelles.
Tanner P; Baumann P; Enea R; Onaca O; Palivan C; Meier W
Acc Chem Res; 2011 Oct; 44(10):1039-49. PubMed ID: 21608994
[TBL] [Abstract][Full Text] [Related]
23. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
Liu Y; Li K; Liu B; Feng SS
Biomaterials; 2010 Dec; 31(35):9145-55. PubMed ID: 20864169
[TBL] [Abstract][Full Text] [Related]
24. Relevant Physicochemical Descriptors of "Soft Nanomedicines" to Bypass Biological Barriers.
Nino-Pariente A; Nebot VJ; Vicent MJ
Curr Pharm Des; 2016; 22(9):1274-91. PubMed ID: 26675217
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of polymeric nanoparticle formulations by effective imaging and quantitation of cellular uptake for controlled delivery of doxorubicin.
Win KY; Teng CP; Ye E; Low M; Han MY
Small; 2015 Mar; 11(9-10):1197-204. PubMed ID: 25400129
[TBL] [Abstract][Full Text] [Related]
26. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
Al-Jamal WT; Kostarelos K
Acc Chem Res; 2011 Oct; 44(10):1094-104. PubMed ID: 21812415
[TBL] [Abstract][Full Text] [Related]
27. Co-opting Moore's law: Therapeutics, vaccines and interfacially active particles manufactured via PRINT®.
DeSimone JM
J Control Release; 2016 Oct; 240():541-543. PubMed ID: 27423326
[TBL] [Abstract][Full Text] [Related]
28. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles.
Reis CP; Neufeld RJ; Ribeiro AJ; Veiga F
Nanomedicine; 2006 Mar; 2(1):8-21. PubMed ID: 17292111
[TBL] [Abstract][Full Text] [Related]
29. Insights into cellular uptake of nanoparticles.
Kafshgari MH; Harding FJ; Voelcker NH
Curr Drug Deliv; 2015; 12(1):63-77. PubMed ID: 25146441
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, Metabolism, Distribution and Permeability of Nanomedicine.
Ravindran S; Suthar JK; Rokade R; Deshpande P; Singh P; Pratinidhi A; Khambadkhar R; Utekar S
Curr Drug Metab; 2018; 19(4):327-334. PubMed ID: 29512450
[TBL] [Abstract][Full Text] [Related]
31. Nanostructured lipid carriers for targeting drug delivery to the epidermal layer.
Gelfuso GM; Cunha-Filho MS; Gratieri T
Ther Deliv; 2016 Nov; 7(11):735-737. PubMed ID: 27790946
[No Abstract] [Full Text] [Related]
32. Pharmaceutical and biomedical applications of surface engineered carbon nanotubes.
Mehra NK; Jain K; Jain NK
Drug Discov Today; 2015 Jun; 20(6):750-9. PubMed ID: 25601411
[TBL] [Abstract][Full Text] [Related]
33. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.
Morachis JM; Mahmoud EA; Almutairi A
Pharmacol Rev; 2012 Jul; 64(3):505-19. PubMed ID: 22544864
[TBL] [Abstract][Full Text] [Related]
34. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Wang Y; Cai R; Chen C
Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
[TBL] [Abstract][Full Text] [Related]
35. Toxicity of novel nanosized formulations used in medicine.
El-Ansary A; Al-Daihan S; Bacha AB; Kotb M
Methods Mol Biol; 2013; 1028():47-74. PubMed ID: 23740113
[TBL] [Abstract][Full Text] [Related]
36. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research.
Elzoghby AO
J Control Release; 2013 Dec; 172(3):1075-91. PubMed ID: 24096021
[TBL] [Abstract][Full Text] [Related]
37. Targeting nanoparticles to cancer.
Wang M; Thanou M
Pharmacol Res; 2010 Aug; 62(2):90-9. PubMed ID: 20380880
[TBL] [Abstract][Full Text] [Related]
38. The performance of nanocarriers for transmucosal drug delivery.
Csaba N; Garcia-Fuentes M; Alonso MJ
Expert Opin Drug Deliv; 2006 Jul; 3(4):463-78. PubMed ID: 16822222
[TBL] [Abstract][Full Text] [Related]
39. Polymeric micelles as drug carriers: their lights and shadows.
Yokoyama M
J Drug Target; 2014 Aug; 22(7):576-83. PubMed ID: 25012065
[TBL] [Abstract][Full Text] [Related]
40. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.
Lanza GM; Winter PM; Caruthers SD; Hughes MS; Cyrus T; Marsh JN; Neubauer AM; Partlow KC; Wickline SA
Nanomedicine (Lond); 2006 Oct; 1(3):321-9. PubMed ID: 17716162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
